Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis
about
CMV: Prevention, Diagnosis and TherapyDelayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation.Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation.Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome.Perforation of the gallbladder in a patient with acute cytomegalovirus cholecystitis shortly following renal transplantation.Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation.It's not too late: a proposal to standardize the terminology of "late-onset" cytomegalovirus infection and disease in solid organ transplant recipients.
P2860
Q26824869-B071D164-74AF-4D21-834D-8690EBC3F161Q33911369-1E4EC935-263A-4A3B-B60E-8401D241571CQ33912913-D5B51AB4-7C47-4950-824A-7F116A9448FDQ35990217-0FACC645-57A3-4DE0-BE86-165FA012BE7EQ36759073-8E101817-F528-4B9A-ADD2-0BAD4615BD41Q37202784-5931EF78-854D-484C-9F71-57936E017B92Q37962447-73DBBC59-FB49-4342-94EB-D5C361F304D5Q38044829-C0304AC7-EEAB-474C-BF6D-05196C0FCE64Q39321579-F0EBE923-21DF-48CD-B764-B1817CBCD45CQ41177320-E5389BC2-1921-4E30-9F17-C3B77199F003Q43517533-ECCFCAC5-D074-40AF-8EB3-D9E1AFA1330CQ44100013-10DD1661-1136-4319-A231-40A3A17EBD51Q45391655-860BAD67-B4C0-4C21-98D9-0A5B8306136FQ50910864-81C15483-8BD9-434E-A458-1D26D6FF3E15
P2860
Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Risk factors for late-onset cy ...... receive antiviral prophylaxis
@ast
Risk factors for late-onset cy ...... receive antiviral prophylaxis
@en
type
label
Risk factors for late-onset cy ...... receive antiviral prophylaxis
@ast
Risk factors for late-onset cy ...... receive antiviral prophylaxis
@en
prefLabel
Risk factors for late-onset cy ...... receive antiviral prophylaxis
@ast
Risk factors for late-onset cy ...... receive antiviral prophylaxis
@en
P2093
P2860
P1476
Risk factors for late-onset cy ...... receive antiviral prophylaxis
@en
P2093
A A Boudreault
A P Limaye
R M Rakita
P2860
P304
P356
10.1111/J.1399-3062.2011.00624.X
P577
2011-03-17T00:00:00Z